Gateway Investment Advisers LLC Buys 30,640 Shares of Johnson & Johnson (JNJ)
Gateway Investment Advisers LLC increased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 2.1% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,484,213 shares of the company’s stock after acquiring an additional 30,640 shares during the period. Johnson & Johnson comprises approximately 1.8% of Gateway Investment Advisers LLC’s investment portfolio, making the stock its 6th largest holding. Gateway Investment Advisers LLC owned 0.06% of Johnson & Johnson worth $196,347,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in JNJ. Lenox Wealth Advisors Inc. grew its position in shares of Johnson & Johnson by 0.6% in the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after acquiring an additional 5 shares during the period. Harel Insurance Investments & Financial Services Ltd. increased its stake in shares of Johnson & Johnson by 241.0% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock worth $149,000 after purchasing an additional 841 shares during the last quarter. Ullmann Financial Group Inc. acquired a new position in shares of Johnson & Johnson during the 1st quarter worth about $186,000. Taylor Wealth Management Partners increased its stake in shares of Johnson & Johnson by 19.8% during the 1st quarter. Taylor Wealth Management Partners now owns 1,510 shares of the company’s stock worth $188,000 after purchasing an additional 250 shares during the last quarter. Finally, Foundation Resource Management Inc. acquired a new position in shares of Johnson & Johnson during the 1st quarter worth about $204,000. Institutional investors and hedge funds own 65.90% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Gateway Investment Advisers LLC Buys 30,640 Shares of Johnson & Johnson (JNJ)” was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.watchlistnews.com/gateway-investment-advisers-llc-buys-30640-shares-of-johnson-johnson-jnj/1605781.html.
In related news, VP Dominic J. Caruso sold 82,591 shares of the business’s stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $136.72, for a total value of $11,291,841.52. Following the sale, the vice president now directly owns 226,693 shares in the company, valued at approximately $30,993,466.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Paulus Stoffels sold 102,692 shares of the business’s stock in a transaction dated Monday, July 24th. The shares were sold at an average price of $133.14, for a total value of $13,672,412.88. Following the completion of the sale, the vice president now owns 230,342 shares in the company, valued at $30,667,733.88. The disclosure for this sale can be found here. Company insiders own 0.19% of the company’s stock.
Johnson & Johnson (NYSE:JNJ) traded up 0.583% during midday trading on Tuesday, hitting $131.985. 1,820,410 shares of the stock were exchanged. The firm has a market capitalization of $354.25 billion, a P/E ratio of 22.332 and a beta of 0.78. Johnson & Johnson has a 1-year low of $109.32 and a 1-year high of $137.08. The firm’s 50-day moving average price is $132.31 and its 200 day moving average price is $129.75.
Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.79 by $0.04. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The firm had revenue of $18.84 billion for the quarter, compared to analyst estimates of $18.94 billion. During the same period in the previous year, the company posted $1.74 earnings per share. The business’s revenue was up 1.9% on a year-over-year basis. Analysts expect that Johnson & Johnson will post $7.18 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th were paid a dividend of $0.84 per share. The ex-dividend date was Friday, August 25th. This represents a $3.36 annualized dividend and a dividend yield of 2.56%. Johnson & Johnson’s payout ratio is 56.76%.
A number of brokerages have recently issued reports on JNJ. UBS AG reaffirmed a “buy” rating and issued a $148.00 target price on shares of Johnson & Johnson in a report on Saturday. Zacks Investment Research downgraded shares of Johnson & Johnson from a “hold” rating to a “sell” rating in a research note on Wednesday, September 27th. Citigroup Inc. initiated coverage on Johnson & Johnson in a report on Monday, September 25th. They set a “neutral” rating and a $140.00 price target for the company. Goldman Sachs Group, Inc. (The) cut Johnson & Johnson from a “neutral” rating to a “sell” rating and lifted their price target for the stock from $125.00 to $130.00 in a report on Wednesday, September 20th. Finally, Vetr downgraded Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 price target on the stock. in a research report on Monday, September 18th. Six analysts have rated the stock with a sell rating, eight have given a hold rating and eight have given a buy rating to the company. Johnson & Johnson currently has an average rating of “Hold” and a consensus target price of $135.52.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.